PMID- 15838706
OWN - NLM
STAT- MEDLINE
DCOM- 20050602
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 54
IP  - 6
DP  - 2005 Jun
TI  - New developments in dendritic cell-based vaccinations: RNA translated into 
      clinics.
PG  - 517-25
AB  - Dendritic cells (DCs) are the most powerful antigen-presenting cells that induce 
      and maintain primary immune responses in vitro and in vivo. The development of 
      protocols for the ex vivo generation of DCs provided a rationale for designing 
      and developing DC-based vaccination studies for the treatment of infectious and 
      malignant diseases. Recently, it was shown that DCs transfected with ribonucleic 
      acid (RNA) coding for a tumour-associated antigen or whole tumour RNA are able to 
      induce potent antigen and tumour-specific T-cell responses directed against 
      multiple epitopes. The first RNA-transfected-DC-based clinical studies have shown 
      that this form of vaccination is feasible and safe. In some cases, clinical 
      responses were observed, but the preliminary data require further extensive 
      investigations that should address the technical and biological problems of 
      manipulating human DCs, as well as the development of standardised protocols and 
      definitions of clinical settings.
FAU - Grunebach, Frank
AU  - Grunebach F
AD  - Department of Internal Medicine II, Division of Hematology, Immunology, and 
      Oncology, University of Tubingen, Otfried-Muller-Str. 10, 72076, Tubingen, 
      Germany.
FAU - Muller, Martin R
AU  - Muller MR
FAU - Brossart, Peter
AU  - Brossart P
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20050127
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Cancer Vaccines)
RN  - 0 (RNA, Neoplasm)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Neoplasms/*therapy
MH  - RNA, Neoplasm/*genetics
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Transfection
MH  - *Vaccination
PMC - PMC11032897
EDAT- 2005/04/20 09:00
MHDA- 2005/06/03 09:00
PMCR- 2005/01/27
CRDT- 2005/04/20 09:00
PHST- 2004/06/24 00:00 [received]
PHST- 2004/07/27 00:00 [accepted]
PHST- 2005/04/20 09:00 [pubmed]
PHST- 2005/06/03 09:00 [medline]
PHST- 2005/04/20 09:00 [entrez]
PHST- 2005/01/27 00:00 [pmc-release]
AID - 605 [pii]
AID - 10.1007/s00262-004-0605-x [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2005 Jun;54(6):517-25. doi: 10.1007/s00262-004-0605-x. 
      Epub 2005 Jan 27.